Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
AZN
#5230
AstraZeneca PLC - American Depositary Shares
164.5
1
USD
-0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.09%
Monthly Change
-5.51%
6 month change
-20.04%
Year Change
+106.70%
Previous Close
166.3
2
Open
164.7
3
Low
164.3
7
High
164.9
4
Volume
1 267
Markets
US Stock Market
Healthcare
Drug Manufacturers—General
AZN
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q4, 25
Current
Key stats
Total common shares outstanding
—
—
Valuation ratios
Enterprise value
—
—
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
News
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?
Can Eli Lilly's Oncology Portfolio Drive Growth Beyond GLP-1 Drugs?
How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?
Making Drugs With AI: Biopharma Giants Gear Up For New Arena
Merck vs. J&J: Which Healthcare Giant Should Investors Choose?
Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM)
Silence Therapeutics: Making Some Recent Noise (NASDAQ:SLN)
Pfizer's Obesity Push: Can Berobenatide Take Market Share?
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment